Cargando…

Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer

PURPOSE: An improved mechanistic understanding of immunosuppressive pathways in non-small cell lung cancer (NSCLC) is important to develop novel diagnostic and therapeutic approaches. Here, we investigate the prognostic significance of the ectonucleotidases CD39 and CD73 in NSCLC. EXPERIMENTAL DESIG...

Descripción completa

Detalles Bibliográficos
Autores principales: Koppensteiner, Lilian, Mathieson, Layla, Pattle, Samuel, Dorward, David A, O’Connor, Richard, Akram, Ahsan R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471883/
https://www.ncbi.nlm.nih.gov/pubmed/37648263
http://dx.doi.org/10.1136/jitc-2023-006770
_version_ 1785099950130987008
author Koppensteiner, Lilian
Mathieson, Layla
Pattle, Samuel
Dorward, David A
O’Connor, Richard
Akram, Ahsan R
author_facet Koppensteiner, Lilian
Mathieson, Layla
Pattle, Samuel
Dorward, David A
O’Connor, Richard
Akram, Ahsan R
author_sort Koppensteiner, Lilian
collection PubMed
description PURPOSE: An improved mechanistic understanding of immunosuppressive pathways in non-small cell lung cancer (NSCLC) is important to develop novel diagnostic and therapeutic approaches. Here, we investigate the prognostic significance of the ectonucleotidases CD39 and CD73 in NSCLC. EXPERIMENTAL DESIGN: The expression and localization of CD39, CD73 and CD103 was digitally quantified in a cohort of 162 early treatment naïve NSCLC patients using multiplex-immunofluorescence and related to patient outcome. Expression among different cell-populations was assessed via flow cytometry. Targeted RNA-Seq was performed on CD4(+) and CD8(+) T cells from digested NSCLC tumor tissue and single-cell RNA-Seq data was analyzed to investigate the functional significance of CD39(+) T cell populations. RESULTS: We demonstrate that flow cytometry of early untreated NSCLC patients shows an upregulation of CD39 expression in the tumor tissue among natural killer (NK) cells, fibroblasts and T cells. CD73 expression is mainly found among fibroblasts and Epcam+cells in the tumor tissue. Multiplex Immunofluorescence in a cohort of 162 early untreated NSCLC patients demonstrates that CD39 expression is mainly localized in the tumor stroma while CD73 expression is equally distributed between tumor nest and stroma, and high expression of CD39 and CD73 in the tumor stroma is associated with poor recurrence-free survival (RFS) at 5 years. Additionally, we find that CD8+T cells located in the tumor nest express CD103 and the density of CD39+CD103+CD8+ T cells in the tumor nest predicts improved RFS at 5 years. Targeted RNA-Seq shows that the tumor microenvironment of NSCLC upregulates regulatory pathways in CD4(+) T cells and exhaustion in CD8(+) T cells, and analysis of a single cell RNA sequencing dataset shows that CD39(+)CD4(+) cells are enriched in Treg signature gene-sets, and CD39(+)CD103(+) cytotoxic T lymphocyte show gene signatures indicative of an exhausted cytotoxic phenotype with upregulated expression of CXCL13. CONCLUSIONS: Knowledge of patterns of distribution and location are required to understand the prognostic impact of CD39(+) T cell populations in NSCLC. This study provides an improved understanding of spatial and functional characteristics of CD39(+) T cells and their significance to patient outcome.
format Online
Article
Text
id pubmed-10471883
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-104718832023-09-02 Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer Koppensteiner, Lilian Mathieson, Layla Pattle, Samuel Dorward, David A O’Connor, Richard Akram, Ahsan R J Immunother Cancer Immunotherapy Biomarkers PURPOSE: An improved mechanistic understanding of immunosuppressive pathways in non-small cell lung cancer (NSCLC) is important to develop novel diagnostic and therapeutic approaches. Here, we investigate the prognostic significance of the ectonucleotidases CD39 and CD73 in NSCLC. EXPERIMENTAL DESIGN: The expression and localization of CD39, CD73 and CD103 was digitally quantified in a cohort of 162 early treatment naïve NSCLC patients using multiplex-immunofluorescence and related to patient outcome. Expression among different cell-populations was assessed via flow cytometry. Targeted RNA-Seq was performed on CD4(+) and CD8(+) T cells from digested NSCLC tumor tissue and single-cell RNA-Seq data was analyzed to investigate the functional significance of CD39(+) T cell populations. RESULTS: We demonstrate that flow cytometry of early untreated NSCLC patients shows an upregulation of CD39 expression in the tumor tissue among natural killer (NK) cells, fibroblasts and T cells. CD73 expression is mainly found among fibroblasts and Epcam+cells in the tumor tissue. Multiplex Immunofluorescence in a cohort of 162 early untreated NSCLC patients demonstrates that CD39 expression is mainly localized in the tumor stroma while CD73 expression is equally distributed between tumor nest and stroma, and high expression of CD39 and CD73 in the tumor stroma is associated with poor recurrence-free survival (RFS) at 5 years. Additionally, we find that CD8+T cells located in the tumor nest express CD103 and the density of CD39+CD103+CD8+ T cells in the tumor nest predicts improved RFS at 5 years. Targeted RNA-Seq shows that the tumor microenvironment of NSCLC upregulates regulatory pathways in CD4(+) T cells and exhaustion in CD8(+) T cells, and analysis of a single cell RNA sequencing dataset shows that CD39(+)CD4(+) cells are enriched in Treg signature gene-sets, and CD39(+)CD103(+) cytotoxic T lymphocyte show gene signatures indicative of an exhausted cytotoxic phenotype with upregulated expression of CXCL13. CONCLUSIONS: Knowledge of patterns of distribution and location are required to understand the prognostic impact of CD39(+) T cell populations in NSCLC. This study provides an improved understanding of spatial and functional characteristics of CD39(+) T cells and their significance to patient outcome. BMJ Publishing Group 2023-08-30 /pmc/articles/PMC10471883/ /pubmed/37648263 http://dx.doi.org/10.1136/jitc-2023-006770 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Immunotherapy Biomarkers
Koppensteiner, Lilian
Mathieson, Layla
Pattle, Samuel
Dorward, David A
O’Connor, Richard
Akram, Ahsan R
Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
title Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
title_full Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
title_fullStr Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
title_full_unstemmed Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
title_short Location of CD39(+) T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
title_sort location of cd39(+) t cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer
topic Immunotherapy Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471883/
https://www.ncbi.nlm.nih.gov/pubmed/37648263
http://dx.doi.org/10.1136/jitc-2023-006770
work_keys_str_mv AT koppensteinerlilian locationofcd39tcellsubpopulationswithintumorspredictdifferentialoutcomesinnonsmallcelllungcancer
AT mathiesonlayla locationofcd39tcellsubpopulationswithintumorspredictdifferentialoutcomesinnonsmallcelllungcancer
AT pattlesamuel locationofcd39tcellsubpopulationswithintumorspredictdifferentialoutcomesinnonsmallcelllungcancer
AT dorwarddavida locationofcd39tcellsubpopulationswithintumorspredictdifferentialoutcomesinnonsmallcelllungcancer
AT oconnorrichard locationofcd39tcellsubpopulationswithintumorspredictdifferentialoutcomesinnonsmallcelllungcancer
AT akramahsanr locationofcd39tcellsubpopulationswithintumorspredictdifferentialoutcomesinnonsmallcelllungcancer